newsfilter
← Latest News
GlobeNewswire·

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

  • Spero Therapeutics appointed Dr. Debra Jeske Zack as Chief Medical Officer on July 27, 2026.
  • Dr. Zack brings over 25 years of leadership experience in developing therapeutics for immune-mediated diseases.
  • She will lead Spero's clinical development strategy as the company advances SP001, a Phase 2-ready third-generation anti-CD40L antibody.
  • SP001 is designed to treat IgG4-related disease (IgG4-RD) & other immune-mediated conditions by blocking CD40L to modulate B-cell & T-cell activation.
  • The antibody is fully humanized, Fc-silent, & designed to avoid platelet activation issues seen in earlier anti-CD40L therapies.
  • Dr. Zack previously served as Global Development Lead for Enbrel at Amgen & most recently as Chief Medical Officer at Exagen Inc.
  • Her background includes clinical leadership roles at Xencor Inc. & Novartis, along with a 10-year tenure as an associate professor at UCLA.
  • She holds an M.D. & Ph.D. from the University of Texas Southwestern Medical School & completed her residency & fellowship at UCLA.
  • CEO Esther Rajavelu stated Dr. Zack's expertise in rheumatology & autoimmune diseases is vital for initiating clinical development of SP001.
  • Spero Therapeutics is a clinical-stage biopharmaceutical company focused on next-generation medicines in immunology & inflammation.